Danazol is under clinical development by Viramal and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Danazol’s likelihood of approval (LoA) and phase transition for Endometriosis took place on 09 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Danazol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Danazol is under development for the treatment of endometriosis. The drug candidate is formulated as a locally targeted vaginal cream. It acts by targeting androgen receptor, progesterone receptor and estrogen receptor.
Viramal is a pharmaceutical and health care company that provides women’s health products. The company offers discovery and development of therapeutics to improve women’s health. Its products portfolio includes elegant vaginal moisturizer that is used for the treatment of vaginal atrophy and prevention of local infections through pH modification; and testocream and estrogen therapy, among others. Viramal’s products are used in the treatment of menopausal hormone therapy, fertility, contraception and sexual health. The company also provides prescription drugs and non-prescription drugs. It has its operations in the UK and the US. Viramal is headquartered in London, England, the UK.
Quick View Danazol LOA Data
|Highest Development Stage|